Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
CALCIPOTRIOL ANHYDROUS
Rowex Ltd
50 Microgram/ML
Cutaneous Solution
2009-04-08
IRISH MEDICINES BOARD ACTS 1995 AND 2006 MEDICINAL PRODUCTS(CONTROL OF PLACING ON THE MARKET)REGULATIONS,2007 (S.I. NO.540 OF 2007) PA0711/149/001 Case No: 2066595 The Irish Medicines Board in exercise of the powers conferred on it by the above mentioned Regulations hereby grants to ROWEX LTD BANTRY, CO. CORK, IRELAND an authorisation, subject to the provisions of the said Regulations, in respect of the product CALCIL 50 MICROGRAMS/ML CUTANEOUS SOLUTION The particulars of which are set out in Part I and Part II of the attached Schedule. The authorisation is also subject to the general conditions as may be specified in the said Regulations as listed on the reverse of this document. This authorisation, unless previously revoked, shall continue in force from 07/09/2009 until 07/04/2014. Signed on behalf of the Irish Medicines Board this ________________ A person authorised in that behalf by the said Board. IRISH MEDICINES BOARD ________________________________________________________________________________________________________________________ _Date Printed 07/09/2009_ _CRN 2066595_ _page number: 1_ PART II SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Calcil 50 micrograms/ml Cutaneous Solution 2 QUALITATIVE AND QUANTITATIVE COMPOSITION One ml of calcipotriol cutaneous solution contains 50 micrograms calcipotriol. Excipient: Propylene glycol 30 mg/ml. For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Cutaneous solution Clear, colourless solution with an odour of menthol. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Calcil 50 micrograms/ml Cutaneous Solution is indicated for the topical treatment of mild to moderate scalp psoriasis. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION _Adults_ Calcil 50 micrograms/ml Cutaneous Solution should be applied to the affected ar Read the complete document